Wound Care
Customize your policy alerts
Sign up for longevityhealthplanofcolorado Policy UM-019 alerts
Get alerted when Policy UM-019 changes without checking for updates manually.
Monitor payer policy activity
Defines coverage criteria and documentation requirements for wound care services (debridement, negative pressure wound therapy, low-frequency non-contact non-thermal ultrasound/MIST) and states that fluorescent imaging is experimental; applies to Longevity Health Plan of Colorado members.
No material clinical or coverage changes in this revision.
Coverage Criteria
Debridement indications
Debridement is covered when at least ONE of the following conditions is present and documented
If deep tissue pressure injury or Stage II injury progresses to Unstageable, Stage III or Stage IV requiring debridement, documentation supporting progression must be included in the medical record.
Negative Pressure Wound Therapy
NPWT is covered when medical necessity is met and there is documented benefit
Extent and number of NPWT services should be medically necessary and reasonable based on documented evaluation; in palliative situations frequency/duration should be limited and consistent with palliative goals.
MIST Therapy criteria
MIST Therapy is covered when showing documented improvement within initial treatments and within utilization limits
Continuing MIST therapy when no improvement is documented after six treatments is not considered reasonable and necessary.
Documentation exceeding utilization guidelines must include full wound description, progress to date, complications delaying healing, and projected additional treatments to justify further services.
Fluorescent imaging (0598T/0599T)
Fluorescent imaging of wounds
NICE MedTech briefing (2020) cited concerns about small sample sizes, limited outcomes, and need for multicenter randomized controlled trials.
Noncontact real-time fluorescent imaging of wounds (for example, MolecuLight i:X) is considered experimental by the Plan and is not covered. The policy cites insufficient and small-scale evidence, lack of robust outcomes such as wound closure times and antibiotic-use impact, and indicates that higher-quality multicenter randomized trials are needed to establish clinical utility.
For MIST Therapy (low-frequency, non-contact, non-thermal ultrasound), the Plan requires documented improvement after the initial treatment course. If a wound shows no improvement after six MIST treatments (no reduction in pain, necrotic tissue, wound size, or no improved granulation), then continuing MIST is considered not reasonable and necessary and will not be covered. Additionally, utilization limits apply (see policy for the ≤18 services in six weeks threshold).
Coding
Provider Actions & Documentation Requirements
Prior authorization — MIST Therapy continuation criteria
MIST Therapy may continue only when the medical record documents improvement after the first six MIST treatments. The policy limits MIST Therapy to no more than 18 services within any six-week period.
- Documented improvements may include reduction in pain, reduction in necrotic tissue, reduction in wound size, or improved granulation tissue.
- No more than 18 MIST services in a six-week period will be considered reasonable and necessary.
Step therapy — continuation requires documented benefit
Continuation of NPWT or repeated debridement is permitted only when there is documented evidence of clear benefit and ongoing medical necessity for the services provided.
- Documented evidence of clear benefit from prior NPWT or debridement must be present to justify further treatments.
- Services should be limited to what is medically necessary and reasonable based on the patient's documented condition and plan.
Documentation — certified plan of care required
The medical record must include a certified plan of care that states treatment goals, provider follow-up, expected frequency and duration, anticipated endpoint, and measured wound status (surface dimensions and depth).
- Plan must document goals, frequency/duration, expected endpoint, and provider follow-up.
- Wound measurements must include current surface dimensions and depth, signs or absence of infection, and presence or absence of necrotic/devitalized tissue.
- When debridement is reported, procedure notes must describe tissue removed, method used, wound character before/after, and amount of tissue removed.
Documentation — requirements for treatments exceeding utilization guidelines
When documentation exceeds utilization guidelines, include a complete wound description, progress toward healing, complications delaying healing, and a projected number of additional treatments needed.
- Describe wound progress and any complicating factors that have delayed healing.
- Provide a projected number of additional treatments necessary to reach the anticipated endpoint.
Denial risk — unmodified plan when goals unmet
If treatment goals are not being met and the plan of care is not adjusted or modified to address lack of progress, the services may be denied.
- Progress toward documented, measurable goals must be shown and when goals are unmet, appropriate modification of the treatment plan must be demonstrated.
Denial risk — insufficient wound or debridement documentation
Insufficient or missing documentation of wound measurements, infection status, necrotic tissue presence, or debridement procedure details may result in denial of services.
- Medical record must document current wound volume (surface dimensions and depth).
- Documentation must state presence/extent or absence of infection and necrotic/devitalized tissue.
- Debridement notes must include tissue removed, method, before/after descriptions, and amount removed (e.g., sq. cm).
Background
This policy applies to wounds that are refractory to healing or where healing is complicated by wound characteristics or systemic factors, and it defines coverage and documentation expectations for debridement and adjunctive therapies. Debridement is the removal of devitalized or contaminated tissue to expose healthy tissue and promote healing, and is covered when at least one qualifying indication is documented (for example, pressure injuries Stage II–IV progressing to deeper stages, venous or arterial insufficiency ulcers, neuropathic or diabetic foot ulcers, wounds with exposed bone or hardware, dehiscence, or other specified conditions).
The policy also situates debridement within the broader wound-care context: for wounds resistant to prior treatments, therapies such as Negative Pressure Wound Therapy (NPWT) or repeated debridement may be continued only with clear documented benefit and ongoing medical necessity. Medical records must include a certified plan of care with goals, frequency/duration, expected endpoint, wound measurements, infection status, and for debridement specifically, the method, tissue removed, and before/after descriptions to justify continued services.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.